Management of immune-related adverse events resulting from immune checkpoint blockade
出版年份 2018 全文链接
标题
Management of immune-related adverse events resulting from immune checkpoint blockade
作者
关键词
-
出版物
Expert Review of Anticancer Therapy
Volume -, Issue -, Pages 1-14
出版商
Informa UK Limited
发表日期
2018-12-21
DOI
10.1080/14737140.2019.1562342
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists
- (2018) Mauro Frigeri et al. CANADIAN JOURNAL OF CARDIOLOGY
- Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1
- (2018) Ahmed Mekki et al. EUROPEAN JOURNAL OF CANCER
- Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
- (2018) François-Xavier Danlos et al. EUROPEAN JOURNAL OF CANCER
- Nivolumab Induces Sustained Liver Injury in a Patient with Malignant Melanoma
- (2018) Tokuhiro Matsubara et al. INTERNAL MEDICINE
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
- (2018) Eleonora De Martin et al. JOURNAL OF HEPATOLOGY
- Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
- (2018) Syed S. Mahmood et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity
- (2018) John A. Thompson Journal of the National Comprehensive Cancer Network
- Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
- (2018) Javid J Moslehi et al. LANCET
- Muscular disorder related to immune checkpoint inhibitors: forewarned is forearmed
- (2018) Laure Gallay et al. NEURO-ONCOLOGY
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action
- (2018) Tomas G. Neilan et al. ONCOLOGIST
- Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events
- (2018) Jemima Albayda et al. RHEUMATOLOGY
- An overview of the toxicities of checkpoint inhibitors in older patients with cancer
- (2018) Omar Alkharabsheh et al. Journal of Geriatric Oncology
- Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
- (2017) S. Cuzzubbo et al. EUROPEAN JOURNAL OF CANCER
- Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis
- (2017) Sébastien Le Burel et al. EUROPEAN JOURNAL OF CANCER
- Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
- (2017) Myriam Delaunay et al. EUROPEAN RESPIRATORY JOURNAL
- Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review
- (2017) Omar Abdel-Rahman et al. Immunotherapy
- Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer
- (2017) Hisato Kawakami et al. INVESTIGATIONAL NEW DRUGS
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
- (2017) Jarushka Naidoo et al. JOURNAL OF CLINICAL ONCOLOGY
- Fatal Myocarditis Following Treatment with the PD-1 Inhibitor Nivolumab
- (2017) Daniel R. Matson et al. JOURNAL OF FORENSIC SCIENCES
- Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids
- (2017) Mirjana Ziemer et al. JOURNAL OF HEPATOLOGY
- Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy
- (2017) Michael P Brown et al. JOURNAL OF NEUROIMMUNOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Acute liver failure caused by pembrolizumab in a patient with pulmonary metastatic liver cancer
- (2017) Zhenping Wu et al. MEDICINE
- Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer
- (2017) Jia-Hung Chen et al. MEDICINE
- Transient pituitary ACTH-dependent Cushing syndrome caused by an immune checkpoint inhibitor combination
- (2017) Jeremy Lupu et al. MELANOMA RESEARCH
- Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies
- (2017) David J. Byun et al. Nature Reviews Endocrinology
- Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan
- (2017) Shigeaki Suzuki et al. NEUROLOGY
- Myocarditis with Immune Checkpoint Blockade
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature
- (2017) Laura C. Cappelli et al. ARTHRITIS CARE & RESEARCH
- Smoldering myocarditis following immune checkpoint blockade
- (2017) Timothy G. Norwood et al. Journal for ImmunoTherapy of Cancer
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Left Ventricular Dysfunction After Treatment With Ipilimumab for Metastatic Melanoma
- (2016) Mary E. Roth et al. AMERICAN JOURNAL OF THERAPEUTICS
- Myasthenic crisis and polymyositis induced by one dose of nivolumab
- (2016) Toshihiro Kimura et al. CANCER SCIENCE
- Management of toxicities of immune checkpoint inhibitors
- (2016) Lavinia Spain et al. CANCER TREATMENT REVIEWS
- Acute Lymphocytic Myocarditis With Anti-PD-1 Antibody Nivolumab
- (2016) Tomonori Tadokoro et al. Circulation-Heart Failure
- PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course
- (2016) M. Nishino et al. CLINICAL CANCER RESEARCH
- The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma
- (2016) Maria Del Castillo et al. CLINICAL INFECTIOUS DISEASES
- Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
- (2016) V.R. Belum et al. EUROPEAN JOURNAL OF CANCER
- Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
- (2016) Lisa Zimmer et al. EUROPEAN JOURNAL OF CANCER
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma
- (2016) Matteo Simonelli et al. Immunotherapy
- Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
- (2016) L. Marthey et al. Journal of Crohns & Colitis
- Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab
- (2016) Claire F. Friedman et al. JNCI-Journal of the National Cancer Institute
- Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
- (2016) Jeffrey S Weber et al. LANCET ONCOLOGY
- Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung
- (2016) H. Semper et al. LUNG CANCER
- Anti-PD1-induced collagenous colitis in a melanoma patient
- (2016) Barouyr Baroudjian et al. MELANOMA RESEARCH
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment
- (2016) Yonghao Cao et al. NEUROLOGY
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents
- (2016) Jeffrey S. Weber et al. ONCOLOGIST
- Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis
- (2016) Xi Zhang et al. Drug Design Development and Therapy
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
- (2016) Camille Hua et al. JAMA Dermatology
- Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer
- (2016) Tanya J. Williams et al. JAMA Neurology
- Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab
- (2016) Claire F. Friedman et al. JNCI-Journal of the National Cancer Institute
- Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma
- (2016) L. Khoja et al. Cancer Immunology Research
- Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer
- (2016) Mizuki Nishino et al. JAMA Oncology
- Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody
- (2016) Mehmet Asim Bilen et al. Journal for ImmunoTherapy of Cancer
- Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
- (2016) Bridgette A. Kanz et al. Journal for ImmunoTherapy of Cancer
- Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
- (2016) Lucie Heinzerling et al. Journal for ImmunoTherapy of Cancer
- Ipilimumab-associated Hepatitis
- (2015) Melanie Johncilla et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- (2015) S. Champiat et al. ANNALS OF ONCOLOGY
- Infliximab for IPILIMUMAB-Related Colitis--Letter
- (2015) E. Arriola et al. CLINICAL CANCER RESEARCH
- Update on neurological paraneoplastic syndromes
- (2015) Romana Höftberger et al. CURRENT OPINION IN ONCOLOGY
- Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma
- (2015) Takushi Shirai et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- (2015) Troy Z. Horvat et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab-induced toxicities and the gastroenterologist
- (2015) Robert Cheng et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma
- (2015) C. Maurice et al. Cancer Immunology Research
- Targeting the immune system to treat lung cancer: rationale and clinical experience
- (2015) Nicolas Guibert et al. Therapeutic Advances in Respiratory Disease
- Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome
- (2015) Benjamin P Geisler et al. Journal for ImmunoTherapy of Cancer
- Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma
- (2014) B. Liao et al. NEURO-ONCOLOGY
- Ipilimumab associated hepatitis: imaging and clinicopathologic findings
- (2013) Kyung Won Kim et al. INVESTIGATIONAL NEW DRUGS
- Ipilimumab-induced acute severe colitis treated by infliximab
- (2013) Cecile Pagès et al. MELANOMA RESEARCH
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma
- (2012) Sebastian G. Bernardo et al. MELANOMA RESEARCH
- Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy
- (2011) Katarzyna D. Chmiel et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
- (2010) S. J. O'Day et al. ANNALS OF ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started